Sorafenib inhibits several tyrosine protein kinases, including VEGFR, PDGFR and Raf-family kinases, and has been tested in combination with topotecan and cyclophosphamide in relapsed neuroblastoma patients by the New Approaches to Neuroblastoma Therapy (NANT) consortium (NCT02298348) [132]. Here, KDR is linked to neuroblastoma.